| Galvani Bioelectronics | |
| Type: | Subsidiary |
| Industry: | Bioelectronics |
| Parent: | GlaxoSmithKline (55% equity interest) |
| Foundation: | November 2016[1] |
| Founders: | [2] |
| Key People: | Kristoffer Famm (President)[3] |
| Location City: | Stevenage[4] |
| Location Country: | United Kingdom |
Galvani Bioelectronics is a Stevenage, United Kingdom-based[5] bioelectronics R&D company.
It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016. The partnership to form the company was announced on 1 August 2016.
Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner. The initial agreed upon investment between the two companies is up to £540 million over a period of seven years[6] and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions."[7] Additionally, both companies agreed to contribute their existing intellectual property rights.
In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. [8]